Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

NeurogesX Reports Successful Phase III Trial For NGX-4010 In Post-Herpetic Neuralgia

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Firm plans to file with EMEA for peripheral neuropathic pain indication later this year.

You may also be interested in...



Pfizer, Hydra Ink Deal To Develop Novel Ion Channel Antagonists For Pain

Collaboration, valued at $195 million, will focus on transient receptor potential ion channel antagonists for pain.

Depomed’s Gabapentin GR Fails Phase III Postherpetic Neuralgia Study

Outcome is not expected to affect product’s ongoing clinical development for menopausal hot flashes.

Lyrica Scheduling Decision Expected In Second Quarter; Launch To Follow

Pfizer hopes to complete the DEA scheduling process for Lyrica during the second quarter, clearing the way for the launch of the neuropathic pain agent

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS066680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By